# Nexentis Technologies Inc. (NXTS) Source: https://www.quantisnow.com/company/NXTS Generated: 2026-11-15T10:35:50.661Z - Ticker: NXTS - Exchange: NASDAQ - Sector: Industrials - Industry: Agricultural Chemicals - SEC CIK: 0001789192 ## Latest NXTS news and filings - 2026-11-10 21:05 UTC [SEC Form 8-K] [Nexentis Technologies Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities](https://www.quantisnow.com/insight/nexentis-technologies-inc-filed-sec-form-8-k-unregistered-sales-of-6783920) - 2026-11-10 15:53 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Nexentis Technologies Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-nexentis-technologies-inc-6783416) - 2026-11-06 21:30 UTC [SEC Form 8-K] [Nexentis Technologies Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/nexentis-technologies-inc-filed-sec-form-8-k-material-modification-to-6779223) - 2026-11-05 14:00 UTC [Nexentis Announces Reverse Stock Split](https://www.quantisnow.com/insight/nexentis-announces-reverse-stock-split-6775133) - 2026-10-29 11:22 UTC [Nexentis: MitoCareX Completes Initial AI-Powered Computational Screening Milestone with Boltz](https://www.quantisnow.com/insight/nexentis-mitocarex-completes-initial-ai-powered-computational-screening-milestone-with-boltz-6762475) - 2026-10-26 12:16 UTC [Nexentis: MitoCareX Bio Advances AI-Driven Drug Discovery Initiative with Boltz, Completing Initial Computational Screening Stage](https://www.quantisnow.com/insight/nexentis-mitocarex-bio-advances-ai-driven-drug-discovery-initiative-with-boltz-6757115) - 2026-10-22 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Nexentis Technologies Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-nexentis-technologies-inc-6755091) - 2026-10-20 13:36 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Nexentis Technologies Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-nexentis-technologies-inc-6751829) - 2026-10-19 20:05 UTC [SEC Form 8-K] [SEC Form 8-K filed by Nexentis Technologies Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-nexentis-technologies-inc-6750582) - 2026-10-19 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Nexentis Technologies Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-nexentis-technologies-inc-6750573) - 2026-10-19 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Nexentis Technologies Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-nexentis-technologies-inc-6750570) - 2026-10-19 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Nexentis Technologies Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-nexentis-technologies-inc-6750568) - 2026-10-19 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Nexentis Technologies Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-nexentis-technologies-inc-6750567) - 2026-10-19 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Nexentis Technologies Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-nexentis-technologies-inc-6750565) - 2026-10-19 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Nexentis Technologies Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-nexentis-technologies-inc-6750564) - 2026-10-19 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Nexentis Technologies Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-nexentis-technologies-inc-6750562) - 2026-10-19 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Nexentis Technologies Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-nexentis-technologies-inc-6750554) - 2026-10-12 12:07 UTC [Nexentis: MitoCareX Bio Expands Computational Biology Capabilities to Advance Disease-Pathway Analysis](https://www.quantisnow.com/insight/nexentis-mitocarex-bio-expands-computational-biology-capabilities-to-advance-disease-pathway-6743508) - 2026-10-07 11:32 UTC [Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google Cloud](https://www.quantisnow.com/insight/nexentis-mitocarex-bio-deploys-its-computational-drug-discovery-infrastructure-on-6739700) - 2026-10-06 13:30 UTC [SEC Form 8-K] [SEC Form 8-K filed by Nexentis Technologies Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-nexentis-technologies-inc-6738534) - 2026-10-05 20:05 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Nexentis Technologies Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-nexentis-technologies-inc-6736763) - 2026-09-24 11:50 UTC [Leadership Update] [Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board](https://www.quantisnow.com/insight/nexentis-mitocarex-strengthens-its-computational-drug-discovery-capabilities-with-appointment-6724815) - 2026-09-23 11:07 UTC [Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug Discovery](https://www.quantisnow.com/insight/nexentis-mitocarex-evaluates-expanded-protein-capabilities-to-enhance-flexibility-and-6723587) - 2026-09-03 20:05 UTC [SEC Form 8-K] [Nexentis Technologies Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/nexentis-technologies-inc-filed-sec-form-8-k-notice-of-delisting-6705005) - 2026-08-13 20:06 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Nexentis Technologies Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-nexentis-technologies-inc-6680362) - 2026-08-06 20:06 UTC [SEC Form 8-K] [Nexentis Technologies Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits](https://www.quantisnow.com/insight/nexentis-technologies-inc-filed-sec-form-8-k-changes-in-registrants-6668898) - 2026-07-28 12:06 UTC [Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign](https://www.quantisnow.com/insight/nexentis-technologies-subsidiary-mitocarex-bio-selects-transport-protein-candidate-for-6650751) - 2026-07-20 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Nexentis Technologies Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-nexentis-technologies-inc-6641753) - 2026-07-16 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Nexentis Technologies Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-nexentis-technologies-inc-6638850) - 2026-07-13 20:05 UTC [SEC Form S-1] [SEC Form S-1 filed by Nexentis Technologies Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-nexentis-technologies-inc-6635359) - 2026-07-13 20:05 UTC [SEC Form POS AM filed by Nexentis Technologies Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-nexentis-technologies-inc-6635348) - 2026-07-07 12:25 UTC [Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative](https://www.quantisnow.com/insight/nexentis-subsidiary-mitocarex-bio-advances-slc-transporter-drug-discovery-with-6629536) - 2026-06-29 12:20 UTC [Nexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation – Significant Premium to Initial Investment](https://www.quantisnow.com/insight/nexentis-announces-monetization-of-part-of-its-melz-solar-investment-6618359) - 2026-06-23 14:03 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Nexentis Technologies Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-nexentis-technologies-inc-6612151) - 2026-06-22 20:49 UTC [SEC Form 8-K] [Nexentis Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits](https://www.quantisnow.com/insight/nexentis-technologies-inc-filed-sec-form-8-k-entry-into-a-6611063) - 2026-06-22 12:22 UTC [Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery](https://www.quantisnow.com/insight/nexentis-technologies-announces-international-ai-drug-discovery-initiative-between-mitocarex-6610129) - 2026-06-17 11:32 UTC [Nexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases](https://www.quantisnow.com/insight/nexentis-subsidiary-mitocarex-bio-successfully-completed-broad-analysis-of-slc-6605858) - 2026-06-15 10:02 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Nexentis Technologies Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-nexentis-technologies-inc-6601672) - 2026-06-12 20:15 UTC [SEC Form 8-K] [Nexentis Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits](https://www.quantisnow.com/insight/nexentis-technologies-inc-filed-sec-form-8-k-entry-into-a-6600415) - 2026-05-27 20:05 UTC [SEC Form 8-K] [Nexentis Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits](https://www.quantisnow.com/insight/nexentis-technologies-inc-filed-sec-form-8-k-entry-into-a-6574723) ## More - Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/NXTS - Earnings history: https://www.quantisnow.com/earnings/NXTS - Dividend history: https://www.quantisnow.com/dividends/NXTS - Insider transactions: https://www.quantisnow.com/insiders/NXTS - Options chain: https://www.quantisnow.com/options/NXTS - SEC 8-K filings only: https://www.quantisnow.com/company/NXTS/8-k - RSS and alerts for NXTS: https://www.quantisnow.com/docs/rss-feeds.md